Instil Bio (TIL) Price & Analysis

Compare

373 Followers

TIL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.80 - $92.00

Previous CloseN/A

Volume80.17K

Average Volume (3M)134.97K

Market Cap

$197.26M

Enterprise Value$130.32M

Total Cash (Recent Filing)$91.82M

Total Debt (Recent Filing)$6.00K

Price to Earnings (P/E)―

Beta4.95

Next Earnings

Nov 17, 2025

EPS Estimate

-2.36

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.24

Shares Outstanding6,750,716

10 Day Avg. Volume94,623

30 Day Avg. Volume134,970

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue32.70

Enterprise Value/Gross Profit223.54

Enterprise Value/Ebitda-1.65

Forecast

1Y Price Target

$125.00

Price Target Upside312.27% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical DataThe initial AXN-2510 + chemo data in 1L NSCLC shows impressive early efficacy with an 80% partial response rate in squamous NSCLC and a 62% overall partial response rate alongside favorable safety.

Market PotentialThe rising values of these transactions should provide further confidence that the highly positive clinical impact of these PD-1/L1 x VEGF bispecifics is real and highlights potential for Instil Bio to become an acquisition target of interest, given encouraging data generated to date.

ValuationValuation gap highlights upside potential for TIL.

Bears Say

Data LimitationsThe preliminary, small-sample, single-arm nature of the data, paired with immature follow-up and lack of statistical analyses, likely explains why the stock did not react more strongly.

Financial PerformanceInstil reported a 2Q25 net loss of $3.24 per share versus an estimated net loss of $1.72 per share due to a one-time $10M milestone payment.

Instil Bio News

Instil Bio’s Promising Outlook: Buy Rating Supported by Successful Trials and Market Potential

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio today and set a price target...

9d ago

TIL

Instil Bio Receives Buy Rating Amid Promising Trial Data and Strong Financial Outlook

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Instil Bio. The associated price target...

21d ago

TIL

Instil Bio Reports Promising Phase 2 Study Results

The latest announcement is out from Instil Bio ( ($TIL) ). On July 31, 2025, Instil Bio, Inc....

1M ago

TIL

Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510

Instil Bio (TIL) noted that ImmuneOnco Biopharmaceuticals announced preliminary safety and efficacy data from the Phase 2 open-label,...

1M ago

TIL

Instil Bio announces FDA clearance of IND application for AXN-2510

Instil Bio (TIL) announced the clearance of an Investigational New Drug application for AXN-2510 by the U.S. FDA....

2M ago

TIL

Instil Bio adds Maraganore to the Board of Directors of Axion Bio

Instil Bio (TIL) announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio,...

3M ago

TIL

Instil Bio Positioned as a Promising Player in the PD-1/L1 x VEGF Market with Strong Buy Recommendation

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and...

3M ago

TIL

Instil Bio appoints Jamie Freedman as CMO

Instil Bio (TIL) announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Jamie Freedman is...

3M ago

TIL

Instil Bio Elects Director and Ratifies Auditor

Instil Bio ( ($TIL) ) just unveiled an update. On May 28, 2025, Instil Bio, Inc. held its...

3M ago

TIL

Instil Bio Advances Phase 2 Trial in China

The latest update is out from Instil Bio ( ($TIL) ). On May 22, 2025, Instil Bio and...

3M ago

TIL

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

TIL

IMNN

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

CVM

TIL

Instil Bio price target raised to $125 from $105 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Instil Bio (TIL) to $125 from $105 and keeps a...

4M ago

TIL

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

TIL

ARMP

TIL FAQ

What was Instil Bio’s price range in the past 12 months?

Instil Bio lowest stock price was $10.80 and its highest was $92.00 in the past 12 months.

What is Instil Bio’s market cap?

Instil Bio’s market cap is $197.26M.

When is Instil Bio’s upcoming earnings report date?

Instil Bio’s upcoming earnings report date is Nov 17, 2025 which is in 73 days.

How were Instil Bio’s earnings last quarter?

Instil Bio released its earnings results on Aug 13, 2025. The company reported -$3.24 earnings per share for the quarter, missing the consensus estimate of -$2.502 by -$0.738.

Is Instil Bio overvalued?

According to Wall Street analysts Instil Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Instil Bio pay dividends?

Instil Bio does not currently pay dividends.

What is Instil Bio’s EPS estimate?

Instil Bio’s EPS estimate is -2.36.

How many shares outstanding does Instil Bio have?

Instil Bio has 6,750,716 shares outstanding.

What happened to Instil Bio’s price movement after its last earnings report?

Instil Bio reported an EPS of -$3.24 in its last earnings report, missing expectations of -$2.502. Following the earnings report the stock price went up 0.522%.

Which hedge fund is a major shareholder of Instil Bio?

Currently, no hedge funds are holding shares in TIL

Instil Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-51.74%

Trailing 12-Months

Asset Growth

-21.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Instil Bio

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio (TIL) Earnings & Revenues

Historic Earnings Reports

TIL Stock 12 Month Forecast

Average Price Target

$125.00

▲(312.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","126":"$126","38.25":"$38.3","67.5":"$67.5","96.75":"$96.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$125.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,38.25,67.5,96.75,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.23,30.135384615384616,38.04076923076923,45.94615384615385,53.85153846153846,61.75692307692307,69.66230769230769,77.56769230769231,85.47307692307692,93.37846153846154,101.28384615384616,109.18923076923078,117.09461538461538,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.23,30.135384615384616,38.04076923076923,45.94615384615385,53.85153846153846,61.75692307692307,69.66230769230769,77.56769230769231,85.47307692307692,93.37846153846154,101.28384615384616,109.18923076923078,117.09461538461538,{"y":125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.23,30.135384615384616,38.04076923076923,45.94615384615385,53.85153846153846,61.75692307692307,69.66230769230769,77.56769230769231,85.47307692307692,93.37846153846154,101.28384615384616,109.18923076923078,117.09461538461538,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.3,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.25,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.58,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.09,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.26,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.02,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.61,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.65,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >